Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients

To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Inclusion Criteria:

• IBS diarrhea

Exclusion Criteria:

• < 18 years of age
• Pregnancy/breast feeding
• concomitant medications to reduce bowel function